Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2023-05-22 AGM Information
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Informacja o otrzymaniu zgłoszeń kandydatów na Członków Rady Nadzorczej Spółki - Content (PL)
AGM Information Classification · 98% confidence The document text is in Polish and discusses nominations ('zgłoszenia kandydatur') for the Supervisory Board ('Rady Nadzorczej') in connection with the agenda ('porządkiem obrad') of the Ordinary General Meeting ('Zwyczajnego Walnego Zgromadzenia') scheduled for May 25, 2023. It explicitly lists the candidates and states that the company is enclosing ('w załączeniu przekazuje') the candidates' CVs. This content directly relates to the preparation and agenda items for an Annual General Meeting (AGM). Therefore, the most appropriate classification is AGM Information (AGM-R). The document length is short (1051 chars), but its primary function is to convey specific AGM-related nominations, not just announce the publication of a general report.
2023-05-22 Polish
Skrocone sprawozdanie finansowe Pure Biologics S.A. za okres 01.01.2023-31.03.2023_skorygowane
Interim / Quarterly Report Classification · 100% confidence The document is a 'Skrócone sprawozdanie finansowe' (Condensed Financial Report) for Pure Biologics S.A. covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial statements, including the Statement of Profit or Loss, Statement of Financial Position, and various explanatory notes. As it provides comprehensive financial data for a quarterly period (Q1 2023) and is not merely an announcement or a certification, it is classified as an Interim/Quarterly Report. Q1 2023
2023-05-17 Polish
Jednostkowy raport kwartalny Pure Biologics S.A. za okres 01.01.2023-31.03.2023_skorygowany
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Jednostkowy raport kwartalny' (Standalone Quarterly Report) for Pure Biologics S.A. covering the period 01.01.2023 – 31.03.2023. It contains detailed sections on company operations, board composition, financial results, and management commentary. As it is a comprehensive quarterly financial report containing actual financial statements and analysis, it fits the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-17 Polish
Skrocone sprawozdanie finansowe Pure Biologics S.A. za okres 01.01.2023-31.03.2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Skrócone sprawozdanie finansowe' (Condensed Financial Report) for Pure Biologics S.A. covering the period from 01.01.2023 to 31.03.2023. It contains detailed financial statements, including the Statement of Profit or Loss, Statement of Financial Position, and various explanatory notes. Since it covers a period shorter than a full fiscal year (a quarter) and includes substantive financial data, it is classified as an Interim/Quarterly Report. Q1 2023
2023-05-15 Polish
Jednostkowy raport kwartalny Pure Biologics S.A. za okres 01.01.2023-31.03.2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Jednostkowy raport kwartalny' (Standalone Quarterly Report) for Pure Biologics S.A. covering the period from 01.01.2023 to 31.03.2023. It contains detailed sections on company operations, management, financial results, and business outlook, which fits the definition of an Interim/Quarterly Report (IR). It is not a mere announcement (RPA) as it contains substantive financial and operational data. Q1 2023
2023-05-15 Polish
Sprawozdanie Rady Nadzorczej Pure Biologics S.A. z działalności w roku 2022
Audit Report / Information Classification · 95% confidence The document is titled "SPRAWOZDANIE RADY NADZORCZEJ Z DZIAŁALNOŚCI ZA 2022 ROK" (Supervisory Board Report on Activities for 2022). It details the Supervisory Board's assessment of the annual financial statements, the Management Board's activity report, the proposal for covering the net loss for 2022, and an assessment of the company's consolidated situation and internal control systems for the year 2022. This content strongly aligns with the requirements for a comprehensive annual review document, often associated with corporate governance and oversight functions, which is typically part of or closely related to the Annual Report (10-K) or a specific Governance/Audit report. Given the detailed assessment of financial statements, management reports, and internal controls, it fits best under the category of Audit Report / Information (AR) or Governance Information (CGR). However, since it is a formal report from the Supervisory Board covering multiple aspects of governance, financial review, and internal controls for the full year (2022), it is a comprehensive oversight document. In the provided definitions, 'AR' covers 'Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests (excluding full Annual Reports)'. 'CGR' covers 'Report detailing the company's internal rules, board structure, and governance practices.' This document heavily features governance practices (internal controls, risk management, compliance with Good Practices) alongside the audit review. Since it is a formal report detailing the board's oversight and review of the annual performance and controls, 'CGR' (Governance Information) is a very strong fit, as it encompasses the detailed governance and internal control assessment sections (Sections 4, 5, 10, 12 in the index). If it were purely the audited financials, AR would be better, but the focus on governance assessment makes CGR more appropriate for this specific Supervisory Board report structure, which reviews compliance with governance codes and internal systems. FY 2022
2023-05-12 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.